Antengene Corporation Limited (HKG:6996)
4.020
-0.040 (-0.99%)
Jul 10, 2026, 9:44 AM HKT
Antengene Corporation Revenue
In the year 2025, Antengene Corporation had annual revenue of 105.34M CNY with 14.56% growth. Antengene Corporation had revenue of 52.16M in the half year ending December 31, 2025.
Revenue
105.34M CNY
Revenue Growth
+14.56%
P/S Ratio
23.53
Revenue / Employee
816.57K CNY
Employees
129
Market Cap
2.76B HKD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.34M | 13.39M | 14.56% |
| Dec 31, 2024 | 91.95M | 24.65M | 36.62% |
| Dec 31, 2023 | 67.31M | -92.83M | -57.97% |
| Dec 31, 2022 | 160.14M | 131.37M | 456.62% |
| Dec 31, 2021 | 28.77M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 2.00B |
| Viva Biotech Holdings | 1.92B |
| Shandong Boan Biotechnology | 873.36M |
| BioDlink International Company | 831.99M |
| Medtide | 634.40M |
| Laekna | 118.76M |
| HJ Science | 14.54M |
| Jiangsu Recbio Technology | 14.16M |
Antengene Corporation News
- 17 days ago - Antengene Licenses ATG-106 And Grants Option Rights On Undisclosed Bispecific TCE To K2 Therapeutics - Nasdaq
- 3 months ago - Antengene Corporation Earnings release: H2 2025 - Filings
- 3 months ago - Antengene Corporation Slides: H2 2025 - Filings
- 3 months ago - Antengene Corporation Annual report: H2 2025 - Filings
- 4 months ago - Antengene Corporation Transcript: Status update - Transcripts
- 4 months ago - Antengene Corporation Press release: Status update - Filings
- 4 months ago - Antengene Corporation Slides: Status update - Filings
- 7 months ago - Antengene Secures Malaysian Approval For XPOVIO In Relapsed/Refractory DLBCL - Nasdaq